Sensitivities of the various imaging modalities for locating specific NETs80 84–92
| Pancreatic NETs | Tumour and Frequency |
| Dual-phase multi-detector CT | 57–94% |
| MRI | 74–94% |
| EUS | 82–93% |
| SSRS insulinomas | 50–60% |
| SSRS gastrin/VIP/somatostatin | 75% |
| 68Ga DOTATOC PET | 87–96% |
| Primary gastrointestinal NETs | |
| CT enteroclysis | 85% |
| MR enteroclysis | 86% |
| SSRS for detection of lesions in non-pancreatic GI NETs | 86–95% |
| Neuroendocrine liver metastases | |
| CT | 44–82% |
| MRI | 82–95% |
EUS, endoscopic ultrasound; GI, gastrointestinal; MR, magnetic resonance; NET, neuroendocrine tumour; PET, positron emission tomography; SSRS, somatostatin receptor scintigraphy; VIP, vasoactive intestinal peptide.
All of the above sensitivities for detecting tumour are further enhanced by intraoperative ultrasound.